Search | Page 2 | Aplastic Anemia and MDS International Foundation

Search

Search results

  1. Early treatment initiation in lower-risk myelodysplastic syndromes produces an earlier and higher rate of transfusion independence

    ... ( azacitidine , decitabine , or lenalidomide ) timing (≤ 3 vs.>3months from start of TD) on the likelihood ...

    Research Article last updated 09/13/2017 - 8:58am.

  2. Top honor goes to AAMDSIF Medical Advisor

    ... His laboratory discovered the molecular basis of lenalidomide activity in MDS as well as multiple myeloma. Recent studies ...

    Article last updated 08/29/2017 - 7:54am.

  3. Making Progress for Myelodysplastic Syndromes

    ... ), Dacogen ( decitabine ), Revlimid ( lenalidomide ). We consider transplant as a curative option for patients ...

    Article last updated 07/26/2017 - 10:25am.

  4. Outcome of patients treated for myelodysplastic syndromes with 5q deletion after failure of lenalidomide therapy.

    ... While lenalidomide (LEN) is the standard of care for the lower-risk ... 5q deletion and to analyze their outcome after failure of lenalidomide. The median survival following LEN failure was 23 months. We ...

    Research Article last updated 07/11/2017 - 10:11am.

  5. Study of Vadastuximab Talirine (SGN-CD33A; 33A) in Combination With Azacitidine in Patients With Previously Untreated Higher Risk MDS

    ... Received prior treatment for MDS with lenalidomide or hypomethylating agents (HMAs). History of one of the ...

    Clinical Trial last updated 06/19/2017 - 2:44pm.

  6. Randomized Phase II Study of Azacitidine Alone or in Combination With Lenalidomide or With Vorinostat in Higher-Risk Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia: North American Intergroup Study SWOG S1117

    ... (MDS). Whether azacitidine-based combinations with lenalidomide or vorinostat produce superior overall response rates (ORRs) ... on days 1 to 7 of a 28-day cycle); azacitidine plus lenalidomide (10 mg/day on days 1 to 21); or azacitidine plus vorinostat (300 ...

    Research Article last updated 05/22/2017 - 10:52am.

  7. Cellular immune profiling after sequential clofarabine and lenalidomide for high risk myelodysplastic syndromes and acute myeloid leukemia

    ... of four cases receiving sequential clofarabine and lenalidomide for high risk MDS and AML in a phase I study. Our results ...

    Research Article last updated 05/22/2017 - 11:42am.

  8. Outcome of Lower-Risk Patients With Myelodysplastic Syndromes Without 5q Deletion After Failure of Erythropoiesis-Stimulating Agents

    ... treatments, including hypomethylating agents (HMAs), lenalidomide (LEN), and investigational drugs, may be used after ESA ...

    Research Article last updated 04/14/2017 - 9:09am.

  9. Management of lower-risk myelodysplastic syndromes without del5q: Current approach and future trends

    ... agents (ESAs), immunosuppressive therapy (IST), lenalidomide and hypomethylating agents (HMAs). We also discuss the ...

    Research Article last updated 03/22/2017 - 9:46am.

  10. Lenalidomide use in myelodysplastic syndromes: Insights into the biologic mechanisms and clinical applications

    ... to AML among patients with lower-risk MDS (LR-MDS). Lenalidomide is the drug with the most impressive clinical activity in the ... independence and cytogenetic responses. Furthermore, lenalidomide delays progression to AML and prolongs survival among responders. ...

    Research Article last updated 02/21/2017 - 9:34am.